| 17/05/24 | 07:00:08 | 17 May 2024 | | IB Software Enhances Clinical Decision-Making |
| 10/05/24 | 08:15:34 | 10 May 2024 | | Rare Pediatric Disease Designation Granted to GaM |
| 02/05/24 | 12:47:42 | 2 May 2024 | | IB Announces Expanded Access Program for GaM |
| 29/04/24 | 15:26:10 | 29 Apr 2024 | | Publication of Annual Report |
| 05/03/24 | 07:00:11 | 5 Mar 2024 | | Grant of Options |
| 01/03/24 | 08:22:06 | 1 Mar 2024 | | Holding(s) in Company |
| 01/03/24 | 08:20:36 | 1 Mar 2024 | | Holding(s) in Company |
| 26/02/24 | 07:00:03 | 26 Feb 2024 | | Result of Broker Option and Total Voting Rights |
| 22/02/24 | 07:00:06 | 22 Feb 2024 | | Placing and Broker Option |
| 09/02/24 | 12:49:51 | 9 Feb 2024 | | FDA Application Update |
| 02/02/24 | 08:39:32 | 2 Feb 2024 | | IB awarded a $100,000 grant |
| 22/01/24 | 10:05:43 | 22 Jan 2024 | | Holding(s) in Company |
| 15/01/24 | 07:01:00 | 15 Jan 2024 | | Director Dealings and Conversion of CLNs |
| 15/01/24 | 07:00:05 | 15 Jan 2024 | | Holding(s) in Company |
| 10/01/24 | 07:00:01 | 10 Jan 2024 | | IB Launching an Expanded Access Program for GaM |
| 19/12/23 | 14:29:45 | 19 Dec 2023 | | Imaging Biometrics granted FDA “Fast-Track” |
| 05/12/23 | 10:58:08 | 5 Dec 2023 | | IQ-AI Announces Positive Interim Phase 1 Results |
| 20/11/23 | 13:42:56 | 20 Nov 2023 | | Holding(s) in Company |
| 09/11/23 | 11:38:50 | 9 Nov 2023 | | Director Dealing and Conversion of CLNs |
| 08/11/23 | 10:59:44 | 8 Nov 2023 | | Application for Pediatric Rare Disease Designation |
| 06/11/23 | 13:02:11 | 6 Nov 2023 | | Holding(s) in Company |
| 18/10/23 | 14:29:47 | 18 Oct 2023 | | Update Regarding Imaging Biometrics LLC |
| 13/10/23 | 08:55:09 | 13 Oct 2023 | | IB Letter to Shareholders |
| 09/10/23 | 07:00:14 | 9 Oct 2023 | | Orphan Drug Status to GaM and Total Voting Rights |
| 03/10/23 | 11:30:18 | 3 Oct 2023 | | Holding(s) in Company |
| 19/09/23 | 14:32:20 | 19 Sept 2023 | | IQ-AI shares cease trading on the OTCQB |
| 08/09/23 | 07:00:04 | 8 Sept 2023 | | Reduced Gadolinium Approach Validated' |
| 18/08/23 | 12:06:19 | 18 Aug 2023 | | Update on Collaboration Agreement with Mayo Clinic |
| 18/08/23 | 11:20:55 | 18 Aug 2023 | | IB & GE HealthCare Enter into Commercial Agreement |
| 17/08/23 | 07:00:02 | 17 Aug 2023 | | Half-year Report |
| 19/07/23 | 07:00:05 | 19 Jul 2023 | | Imaging Biometrics Installs IB Nimble™ For MCW |
| 13/07/23 | 07:00:03 | 13 Jul 2023 | | Orphan Drug Designation for GaM in Pediatric GBM |
| 27/06/23 | 07:00:06 | 27 Jun 2023 | | Studies Show GaM Inhibits Pediatric Tumor Growth |
| 23/05/23 | 11:02:53 | 23 May 2023 | | Result of AGM |
| 23/05/23 | 07:00:01 | 23 May 2023 | | AGM Statement |
| 03/05/23 | 16:14:48 | 3 May 2023 | | Notice of AGM |
| 26/04/23 | 07:00:10 | 26 Apr 2023 | | Final Results |
| 28/02/23 | 15:52:30 | 28 Feb 2023 | | Orphan Drug Designation Status |
| 13/01/23 | 14:05:23 | 13 Jan 2023 | | Second Price Monitoring Extn |
| 13/01/23 | 14:00:10 | 13 Jan 2023 | | Price Monitoring Extension |
| 13/01/23 | 11:05:26 | 13 Jan 2023 | | Second Price Monitoring Extn |
| 13/01/23 | 11:00:12 | 13 Jan 2023 | | Price Monitoring Extension |
| 10/01/23 | 07:00:02 | 10 Jan 2023 | | Letter to Shareholders |
| 02/12/22 | 11:11:59 | 2 Dec 2022 | | Holding in Company |
| 25/10/22 | 11:00:16 | 25 Oct 2022 | | Price Monitoring Extension |
| 30/09/22 | 07:00:10 | 30 Sept 2022 | | Letter to Shareholders |
| 26/09/22 | 07:00:12 | 26 Sept 2022 | | Issue of Warrants to Employees |
| 16/08/22 | 16:40:40 | 16 Aug 2022 | | Second Price Monitoring Extn |
| 16/08/22 | 16:35:39 | 16 Aug 2022 | | Price Monitoring Extension |
| 16/08/22 | 09:28:44 | 16 Aug 2022 | | Half-year Report |
